Newly developed retatrutide, a combined-action medication targeting both GLP-1 and GIP receptors, is generating considerable buzz within the medical community. Initial clinical research have shown significant reductions in physical weight and gains in physiological markers for people with excess weight . Scientists believe this novel approach may